CQA 206-291 in Parkinson's disease.
CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. Significant improvement was noted in the treatment groups compared to the placebo group. Adverse effects were generally mild and transient. CQA appears to be an effective, well-tolerated agent in the treatment of Parkinson's disease. Nevertheless, because of laboratory-based toxicity concerns, CQA has been withdrawn from further human study and will not be developed clinically.
Pfeiffer
R F
RF
University of Nebraska Medical Center, Section of Neurology, Omaha 68198-2045.
Hofman
R
R
D000203:Activities of Daily Living; D000368:Aged; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004347:Drug Interactions; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D015259:Dopamine Agents; D004873:Ergolines; D007980:Levodopa; C059483:CQA 206-291